Feature | October 17, 2007| Cristen C. Bolan

What Will Burst the Drug-Eluting Bubble?

Ever since the BASKET-LATE study came out suggesting an increase in the rate of death and myocardial infarction in patients treated with drug-eluting stents, the stent market has experienced a mild tremor of its own. Total stent usage has indeed tapered off this year, dropping about 16 percent according to some estimates.*
Still, stent manufacturers are forging ahead – some with plans to roll out new drug-eluting stent platforms in 2008. This optimism is further backed by the FDA’s “Update to FDA Statement on Coronary Drug-Eluting Stents,” in which an FDA Advisory Panel determined that, “The concerns about thrombosis do not outweigh the benefits of drug-eluting stents compared to bare metal stents when drug-eluting stents are implanted within the limits of their approved indications for use.” Never mind that about 60 percent of the time stents are used for “off-label” indications. Regardless, this is presumably good news for patients, physicians, manufacturers and all involved in the deployment of drug-eluting stents.
But drug-eluting stent makers should not become complacent. The newly developed Paclitaxel-eluting angioplasty balloon might prove a formidable competitor. The new balloons are indicated for treating in-stent restenosis and possibly for bifurcations as well. Already available for use in Europe, these balloons deliver medication directly to the lesion site, and reportedly do not leave any metal scaffolding or polymer behind after the procedure that can lead to complications.
The PEPCAD II study, which was presented at this year’s Transcatheter Cardiovascular Therapeutics (TCT) show, marks the first head-to-head comparison of the drug-eluting balloon to a drug-eluting stent. Investigators anticipate that the balloon will prove to have a clear advantage over drug-eluting stents in that the drug compound can be distributed along the entire length of the balloon and better treat the vessel segment.
Although more research is needed, the new balloons might have just what it takes to burst the drug-eluting bubble.

Reference: *Goodroe Healthcare Solutions LLC

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init